clinical trial · NCT04499248
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie·phase2·recruiting·n = 96
Open-angle GlaucomaOcular HypertensionAGN-193408 SRLumiganSham AdministrationLumigan VehicleAGN-193408 SRSham AdministrationLumigan Vehicle
brief summary
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension
started
Nov 16, 2020
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
Mar 23, 2026
official title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol